Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Evergreen Theragnostics, Inc. (“Evergreen”), a radiopharmaceutical contract development and manufacturing organisation, are pleased to announce that the companies have expanded their Targeted Copper Theranostics (TCTs) manufacturing agreement to include next-generation therapeutic products based on 67Cu SAR-Bombesin for Clarity’s planned theranostic trial in the US.
The
new agreement, effective as of today, builds on Clarity and Evergreen’s
existing TCTs manufacturing agreement, entered into on 30 September 2021.
Evergreen will now centrally manufacture and distribute the following products
from its state-of-the-art facility in Springfield, New Jersey, USA:
To
read more please visit:
Clarity
and Evergreen expand Targeted Copper Theranostics manufacturing
Source:
Clarity